Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)


OTC Stock Review Like us on FaceBook! Follow us on Twitter! Connect on LinkedIn

office (404) 856-9157

toll-free (866) 692-6847

email info@otcstockreview.com

OTC Stock Review: Award Winning Small Cap Stock Picks Since 2004

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

    Website: https://rtslco.com
  Rapid Therapeutic Science Laboratories SEC Filings on EDGAR
  https://www.rxoid.com Rxoid metered dose inhaler

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) isn't just another CBD stock. RTSL is a CBD stock with some serious potential. First, let's look at the basics. RTSL is a fully-reporting company with the U.S. Securities and Exchange Commission. This innovative biotech company specializes in aerosol delivery of legal cannabinoids to the systemic blood stream though the pulmonary route of administration, which means you inhale it into your lungs. RTSL's main product is the Rxoid metered dose inhaler (MDI). The Rxoid MDI shares many similar physical characteristics to an asthma inhaler and works the same way by delivering medication directly to a user's blood stream through the pulmonary tract.

Rapid Therapeutic Science Laboratories, Inc. started trading publicly around the end of 2019 and is the low-float play most investors are looking for. With 200,000,000 authorized, RTSL has 156,856,000 issued and outstanding, as of May 6, 2020. Of the 156,856,000 issued and outstanding, 141,000,000 are restricted, 15,856,000 shares are unrestricted, and only 26,000 (not a typo) shares are held in DTC.

RTSL markets its Rxoid MDI product directly to pharmacies and physicians and select distributions chains. You can also buy direct on the Company’s website, so if you want to try Rxoid MDI from RTSL, you can order one online at https://www.rxoid.com/product/rxoid-cbd-inhaler/.


Rxoid is RTSL's flagship product, as well as a breakthrough cannabis device that delivers value for the consumer. Rxoid uses hemp cannabinoid derivatives and, similar to an asthma inhaler, a quick shot, which is easily inhaled, offers safe/effective dosing of CBD. The device features the safest, quality ingredients designed for the fastest acting relief. The use of CBD is exploding across the U. S., as well as the world. There are many stories and a tremendous amount of information about the therapeutic uses for it. The folks at RTSL believe the key to safe and effective CBD use is to leverage the highest quality, natural CBD in the best delivery system.  RTSL management has a wealth of experience in CBD, pharmaceutical and consumer goods and knows that a quality delivery system can be the answer to providing effective relief.

RTSL's Rxoid metered-dose inhaler delivers a precise and fast acting dose of CBD directly to your lungs every time you use it. Not only does it work, Rxoid is manufactured using Current Good Manufacturing Practice (CGMP) standards that are mandated by the FDA with respect to the manufacture of all drugs and medical devices.  This means RTSL uses the highest quality parts and manufacturing processes to ensure that Rxoid upholds a quality delivery system. RTSL management knows it is important to do things to the proper standard in the CBD space, and delivering a 100% safe product is their ultimate goal.

The Rxoid cannabinoid MDI delivers medication directly to a user’s blood stream through the pulmonary tract, but there are many more advantages to using an MDI. MDI’s are generally sterile, stable, will not oxidize and have a long shelf life not affected by light or temperature. MDI’s require neither heat nor batteries. MDI’s are efficient devices to deliver medication to humans whether systemically or topically. Bioavailability of the RTSL’s MDI approaches 98%. Drug bioavailability refers to the extent and rate at which the active drug enters systemic circulation, thereby accessing the site of action. RTSL is also testing CBN blends and psilocybin where legal. RTSL is unique in the MDI industry in that they do not use “full spectrum” oil or any other excipient not approved for human inhalation. RTSL’s MDI are made using FDA listed cans, valves, actuators, propellant and excipients. Not only does Rxoid deliver CBD to the bloodstream faster than most products out there, management has made 100% certain that the product is manufactured to the highest safety standards.

Anxiety, Stress, and Life in General

Everyday life involves dealing with stress and anxiety. We all know people whose lives are filled with drama and every passing moment involves another crisis. More importantly, while some of these people are not medicated, many are on multiple medications. Over the years many of us have looked toward naturally occurring remedies for a safer means of treatment. Although RTSL makes no therapeutic claims about any of its proprietary blends of cannabinoids, a 2015 analysis of multiple studies concluded that cannabinoids, including CBD, are a promising treatment for numerous forms of anxiety, including social anxiety disorder (SAD), panic disorder, obsessive-compulsive disorder, GAD, and post-traumatic stress disorder (PTSD).

On June 10, 2020, RTSL CEO, Donal R. Schmidt, Jr. said in a press release, "The Covid-19 World-Wide Pandemic has sadly harmed many businesses; however, we continue to see strong demand for our existing product lines. Our primary business of manufacturing MDI with cannabinoid bases remains strong. We are moving ahead to formulate, manufacture and distribute new and unique formulations using our proprietary manufacturing processes." People are always going to have stress and anxiety, and RTSL's Rxoid device offers a much more socially acceptable way of getting a fast acting dose of CBD.

CBD does work to relieve stress and anxiety. Washington State University did a study a couple of years ago where scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home. Their work, a summary of which can be found here https://www.sciencedirect.com/science/article/pii/S0165032718303100?via%3Dihub, suggests smoking cannabis can significantly reduce short-term levels of depression, anxiety, and stress but may contribute to worse overall feelings of depression over time. We all knew that in high school and college, right?

In all seriousness, this study marks one of the first attempts by U.S. scientists to assess how cannabis with varying concentrations of the chemical compounds tetrahydrocannabinol (THC) and cannabidiol (CBD) affect medicinal cannabis users' feelings of wellbeing when smoked outside of a laboratory.

"Existing research on the effects of cannabis on depression, anxiety and stress are very rare and have almost exclusively been done with orally administered THC pills in a laboratory," said Carrie Cuttler, clinical assistant professor of psychology at WSU and lead author of the study. "What is unique about our study is that we looked at actual inhaled cannabis by medical marijuana patients who were using it in the comfort of their own homes as opposed to a laboratory."

I'm copying this directly from the sciencedirect.com page, but the highlights of the study show:

1.       Cannabis significantly reduced ratings of depression, anxiety, and stress.

2.       Women reported larger reductions in anxiety as a function of cannabis than did men.

3.       Low THC/high CBD cannabis was best for reducing perceived symptoms of depression.

4.       High THC/high CBD cannabis was best for reducing perceived symptoms of stress.

5.       Use of cannabis to treat depression appears to exacerbate depression over time.

A quick Google search will turn up countless other studies that say the same thing. CBD helps to relieve stress and anxiety.


Just about everyone reading this article either uses CBD, or knows someone who uses CBD. In case you haven't noticed, there are CBD stores popping up all over the place, and even the mainstream retailers are selling CBD products. As CBD gained in popularity, every little company with a stock symbol jumped on the bandwagon and said they were in the CBD business. The truth of the matter is, only a few of them actually have a product. If you drill down even more, most of the companies that do have a product do not have anything spectacular. After all, how many companies can possibly be making CBD gummies? RTSL's management team has spent almost 50 years in the cannabis space, and the Company was founded on the basis of aerosol manufacturing. RTSL has wrecked the curve with its disruptive technology and unique formulations which were specifically designed to meet the needs of their customers looking for line extensions to their typical tinctures, gummies, and oils.

The cannabis sector took a beating and most stocks have yet to recover. The CBD sector promises to be one of the most exciting and profitable areas of the market. Do your homework. Learn from all the mistakes other investors have made in the cannabis sector. This is not about recreational use; this is about sound science and research. The big winners are going to be those companies marketing a unique and revolutionary product, like Rxoid. Put Rapid Therapeutic Science Laboratories, Inc. (RTSL) on your quote screen and make sure you stay on top of this great little company. Also, do not forget you can also try a Rxoid MDI for yourself. You can order one online at https://www.rxoid.com/product/rxoid-cbd-inhaler/.


Rapid Therapeutic Science Laboratories, Inc.

Price $0.81


Market Cap: $117.6 million

Shares Outstanding: 157 million

5580 Peterson Lane, Suite 200
Dallas, TX 75240

Phone: (800) 497-6059

Email: investor@rtslco.com

Website: www.rtslco.com 

Website: www.rxoid.com